Navigation Links
NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
Date:12/7/2007

MAPLE GROVE, Minn., Dec. 7 /PRNewswire/ -- NeuroVasx, Inc. announced today the completion of a private placement of common stock in the amount of $8,500,000 with MJSK of Minneapolis, MN and the Stephens Group of Little Rock, AR. Terms of the financing were not disclosed.

The company also announced completion of long term follow up on 20 patients treated with the cPAX Aneurysm Treatment System in a clinical study which was completed in May. The company intends to announce the results of the study at the 2008 International Stoke Conference in February.

"We are very pleased with the results we achieved in our clinical study. The long term follow-up data further supports the clinical effectiveness of cPAX," said Eric Timko, President and CEO of NeuroVasx, Inc. Mr. Timko added, "The company is eager to share the results of our study with the physician community."

Dan Sullivan, Chairman of the Board stated, "The clinical results are a significant milestone for NeuroVasx. We are very pleased with the company's continued progress."

NeuroVasx, Inc. (http://www.neurovasx.com) is a development stage company dedicated to the development of unique catheter and implant technologies to treat acute stroke, aneurysms and other cerebrovascular disorders. Stroke is the third leading cause of death and is the leading cause of adult disability in the United States. The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.


'/>"/>
SOURCE NeuroVasx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DIEGO , Feb. 8, 2016 /PRNewswire/--  Cell ... announced that advanced tissue-engineering services are now available ... a groundbreaking new three-dimensional (3D) bioprinting approach called ... 3D Bio Printer , a state-of-the-art robotic system ... has created a powerful pay-for-service bio-printing model that ...
(Date:2/8/2016)... , Feb. 8, 2016 ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... AUSTIN (PRWEB) , ... February 08, 2016 , ... Remember ... next time. , According to Perry A~, author of “Calcium Bentonite Clay” the ... a key role in balancing and detoxifying the body. , A former motivational speaker, ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's ... organizations. DocuSyst provides a cloud hosted environment for FileHold software that is ... with various 3rd party applications using the FileHold web services API. DocuSyst also ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
Breaking Medicine News(10 mins):